![Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study - Uwe Reuter, John H Krege, Louise Lombard, Elisa Gomez Valderas, Judith Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study - Uwe Reuter, John H Krege, Louise Lombard, Elisa Gomez Valderas, Judith](https://journals.sagepub.com/cms/10.1177/03331024211048507/asset/images/large/10.1177_03331024211048507-fig1.jpeg)
Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study - Uwe Reuter, John H Krege, Louise Lombard, Elisa Gomez Valderas, Judith
![Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients | Scientific Reports Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-68149-1/MediaObjects/41598_2020_68149_Fig1_HTML.png)
Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients | Scientific Reports
![PDF) Costs and Utilization of Triptan Users Who Receive Drug Prophylaxis for Migraine Versus Triptan Users Who Do Not Receive Drug Prophylaxis PDF) Costs and Utilization of Triptan Users Who Receive Drug Prophylaxis for Migraine Versus Triptan Users Who Do Not Receive Drug Prophylaxis](https://i1.rgstatic.net/publication/7968961_Costs_and_Utilization_of_Triptan_Users_Who_Receive_Drug_Prophylaxis_for_Migraine_Versus_Triptan_Users_Who_Do_Not_Receive_Drug_Prophylaxis/links/5650d35308aefe619b155756/largepreview.png)
PDF) Costs and Utilization of Triptan Users Who Receive Drug Prophylaxis for Migraine Versus Triptan Users Who Do Not Receive Drug Prophylaxis
Jeff Maass, Psy.D. - Associate Director, Movement Disorders & Psychiatry MSL team - Teva Pharmaceuticals | LinkedIn
![Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injection) at European Academy of Neurology Congress | Business Wire Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injection) at European Academy of Neurology Congress | Business Wire](https://mms.businesswire.com/media/20200521005736/en/739014/23/teva_RGB_JPEG.jpg)